Most impressive and impactful advances in CV diagnostics and therapies came in the last 50 years from CV engineering, including implantable devices and imaging technology. CV engineers are developing next breakthrough technology including tissue engineering and flexible electronics. However, organizational structure of NIH does not have an entity responsible for strategic development of CV engineering. NIBIB does not ...more »
There is a need to establish virtual CV biologic tissues and a bioinformational repository for specific CV diseases, including congenital cardiovascular malformations, genetic or other unique cardiomyopathies, such as stress cardiomyopathy and giant cell myocarditis.
Can we develop improved, clinically effective tissue engineered constructs for vascular disease?
For replacement valves to achieve durable success, what are the best cell type(s), scaffold design, imaging approaches, and scalable manufacturing approaches?
Many lung diseases (IPF, COPD) are characterized by marked heterogeneity at the tissue level. Unfortunately, most of the tools we currently employ to understand lung disease are unable to elucidate the mechanisms that result in regional heterogeneity. Clinical studies and animal models, while invaluable, generally assume that all lung tissue is similarly affected based on the presence or absence of diagnostic criteria ...more »